In a study in which juvenile dogs received lisdexamfetamine dimesylate for 6 months beginning at 10 weeks of age, decreased bodyweight gain was seen at all doses tested (2, 5, and 12 mg/kg/day, which are approximately 0.5, 1, and 3 times the maximum recommended human daily dose on a mg/m2 basis for a child)
Heisterkamp, N., Groffen, J., Warburton, D
DOI: 10.1056/NEJM199508313330902 Ferrannini & DeFronzo (2015): Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes
69,70 Recent evidence suggests a central nervous system component, as a modified exenatide with reduced brain penetration caused less vomiting in animal models while preserving glucose-lowering effects
11, 2021, article 596130, Steiner, Benjamin M., and Daniel C
Tiotropium, marketed under the brand name Spiriva, has been proven to consistently reduce the risk of COPD exacerbations, while providing long-term quality of life benefits and a favourable impact on survival